NEJM Retracts Tavneos Pivotal Trial; Ionis Tryngolza PDUFA Today

Lilly's Foundayo diabetes filing is due to the FDA today, and tomorrow its fifty-dollar Medicare pricing goes live — the oral GLP-1 race against Novo just got a concrete price tag.

Meanwhile, Vistagen crashed more than seventy percent on a second consecutive Phase 3 miss, the FDA rejected two more drugs over manufacturing failures, and the NEJM just retracted the pivotal study behind Amgen's Tavneos. Loaded Tuesday. Let's get into it.

Welcome to The Pharma Closeout for Tuesday, June 30th, 2026. I'm Alex Mercer.

And I'm Maya Patel.

Before we get into the Foundayo story — a correction we owe you. Yesterday we referenced an orforglipron FDA decision date for today. That was imprecise. The obesity approval already came through on April first under the National Priority Voucher program. What's actually happening today is a filing milestone — Lilly committed to submitting the Foundayo diabetes NDA to the FDA by end of Q2, and they plan to use another priority voucher to compress the review timeline.

Filing versus approval — the distinction matters because one starts a regulatory clock and the other starts revenue. But the data package behind this submission is formidable. The ACHIEVE trials presented at ADA showed Foundayo beating oral semaglutide on both A1C control and weight loss across three pivotal studies. With a priority voucher compressing the review, the diabetes approval could land within months rather than the standard cycle.

And the commercial infrastructure isn't waiting. Starting tomorrow, Medicare Part D patients access Foundayo at fifty dollars a month. Self-pay runs $149 for the lowest dose. Commercial coverage starts at twenty-five through LillyDirect with free home delivery. The label carries a practical edge — no fasting, no water restrictions — which lowers the barrier in primary care settings. LLY dipped about two percent today on China trade headwinds, but the strategic story is Foundayo positioning against Rybelsus in diabetes.

I'd pump the brakes on the market-capture framing. Novo has years of real-world prescribing data behind Rybelsus. Formularies are locked in. And primary care physicians aren't typically poring over head-to-head trial data at the molecule level — they prescribe what's on formulary and what their rep put in front of them. Superior clinical data is necessary but almost never sufficient to flip an installed prescribing base.

The prescribing inertia is real. But Lilly isn't running a molecule-versus-molecule fight here. They're running a channel fight. LillyDirect, free delivery, fifty-dollar government pricing — that entire apparatus is designed to compress time-to-share in ways the traditional formulary playbook can't match.

And that's where the diabetes filing connects to the bigger picture. The pressure on Novo isn't any single readout — it's Lilly building a vertically integrated oral GLP-1 ecosystem across both obesity and diabetes while Novo launches indication by indication through conventional channels. If that distribution architecture delivers, the channel gap could end up mattering more than any clinical delta on a trial endpoint.

The strategic read: if you're modeling oral GLP-1 share over the next three years, the variable to watch isn't the data. It's whether Lilly's direct-to-patient model outpaces Novo's formulary-first approach. Same molecule class, same prescribers, same patients — fundamentally different go-to-market architectures.

That infrastructure play only runs if the molecules deliver. Shifting to the deal and pipeline side — not every program got good news today. Vistagen shares collapsed, down more than seventy percent to close at twenty-two cents, after PALISADE-4 missed the primary endpoint on SUDS scores versus placebo in social anxiety disorder. Back-to-back Phase 3 failures on the same measure.

And the proposed path forward has a fundamental problem. The company wants a new Phase 3 using the Liebowitz Social Anxiety Scale as the primary endpoint instead. But SUDS captures acute, real-time distress during a provocation challenge — it's the sharper test of whether an intranasal drug delivers rapid anxiolysis in the moment it's needed. If fasedienol can't clear that bar twice, pivoting to a scale that measures broader anxiety over a longer arc doesn't address the core mechanism question. It sidesteps it. At twenty-two cents, the market sees that clearly.

On the deal side — Ipsen is acquiring Kartos Therapeutics for up to $1.75 billion, $450 million upfront. The asset is navtemadlin, a Phase 3 MDM2 inhibitor targeting myelofibrosis patients with suboptimal ruxolitinib response. Phase 3 POIESIS data expected next year. Ipsen continues building its hematology-oncology franchise through disciplined bolt-ons with near-term registrational catalysts.

Sanofi posted Phase 3 data for Nexviazyme in infantile-onset Pompe disease — treatment-naive patients six months and younger, alive and free of invasive ventilation at fifty-two weeks. In this population, the untreated disease trajectory is devastating. That data package strengthens Sanofi's position for a potential label expansion into the youngest, most severe segment.

Viridian secured an FDA nod for Lumvoa in thyroid eye disease, which breaks Amgen's monopoly with Tepezza. A second approved TED option gives payers negotiating leverage they haven't had — and that reprices the market for both drugs.

A few more quick hits. BioCryst is shutting down all internal discovery and closing its Birmingham, Alabama facility by year-end — everything moves to external partnerships now, with Orladeyo as the sole commercial engine. Gilead confirmed 108 layoffs effective today. And AbbVie and Genmab reported what analysts are calling redemptive data for Epkinly in diffuse large B-cell lymphoma, a program that needed a strong showing after earlier stumbles.

The BioCryst and Gilead moves reflect the same calculus — mid-caps and even large caps tightening the perimeter around revenue-generating assets and shedding what doesn't contribute to near-term performance. Internal discovery at mid-cap scale is increasingly a luxury the balance sheet won't carry.

Also worth noting on the regulatory side — the FDA's patience with contract manufacturers has hit a wall. Unicycive just received its second complete response letter for its hyperphosphatemia drug, rejected over the exact same third-party manufacturing deficiencies that triggered the first CRL one year ago today. Stock dropped more than fifty percent.

And the CEO's language is nearly verbatim from twelve months ago — optimistic about reinspection, plans to expeditiously resubmit. Same plant. Same deficiencies. Same result. Unicycive isn't isolated either. Sobi and Lantheus both took manufacturing CRLs just yesterday. Earlier this year — AbbVie, Grace Therapeutics, Incyte. The FDA is drawing a line on production quality, and it is not blinking.

For anyone outsourcing manufacturing: your CDMO's inspection readiness is now a gating variable at the NDA level. A pristine clinical package is table stakes if the production facility can't pass review. That risk needs to move up every company's priority list.

Now — the other regulatory story, and this one sits in a different category entirely. The New England Journal retracted the pivotal Phase 3 study for Amgen's Tavneos in ANCA vasculitis. The retraction notice states that primary endpoint assessments in nine patients were readjudicated after database lock and trial unblinding. The drug was developed by ChemoCentryx before Amgen's $3.7 billion acquisition.

Readjudicating endpoints after unblinding is not a procedural footnote. It is a fundamental breach of trial conduct, and the NEJM has now formally documented it through retraction. The FDA already asked Amgen to pull Tavneos from the market. Amgen refused, hired Duke to run an independent re-adjudication, and faces a hearing submission deadline of July 29th. But the terrain shifted under them this week. Defending a drug whose foundational study has been pulled from the world's most prominent medical journal is a categorically different fight than it was seven days ago.

Looking ahead to tomorrow. Foundayo's fifty-dollar Medicare Part D pricing goes live July first. Early uptake in the government channel will tell us whether Lilly's affordability play converts to actual prescription volume or stalls in administrative friction.

Also watching the FDA's cell and gene therapy office — the division head is stepping down after just one year. Leadership transitions at review divisions have historically introduced timeline uncertainty. Any company with a CGT program under review needs to factor that in.

And the FDA named its first PreCheck pilot cohort — Lilly, Regeneron, Fujifilm, and four others. The program clears manufacturing facility reviews upstream of an NDA submission, which connects directly to the CRL wave we just covered. Companies that get ahead of the manufacturing review before filing could avoid the kind of year-long delays Unicycive is living through right now.

And that is your Pharma Closeout for Tuesday, June 30th — Foundayo's diabetes filing and fifty-dollar pricing, Vistagen at twenty-two cents, Ipsen's myelofibrosis bet, the FDA's widening manufacturing crackdown, and an NEJM retraction that puts Tavneos in genuinely uncharted territory. If you want to stay across this space, follow us on Spotify and drop a rating — we're back tomorrow.

Medicare pricing goes live in the morning and Amgen's hearing clock is ticking. We'll have the read on both. See you tomorrow.